Pyxis Oncology (PYXS) Consolidated Net Income (2020 - 2025)
Pyxis Oncology (PYXS) reported Consolidated Net Income of -$18.1 million for Q4 2025, up 49.06% year-over-year from -$12.2 million in Q4 2024, and up 17.65% on a QoQ basis from -$22.0 million in Q3 2025.
Pyxis Oncology (PYXS) has 6 years of Consolidated Net Income data on file, last reported at -$18.1 million in Q4 2025.
- Quarterly Consolidated Net Income rose 49.06% year-over-year to -$18.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$79.9 million (down 0.57% YoY) and the FY2025 annual result came in at -$79.6 million, down 2.98% from the prior year.
- Consolidated Net Income advanced to -$18.1 million in Q4 2025 per PYXS's latest filing, from -$22.0 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$5.3 million in Q1 2024 and bottomed at -$36.1 million in Q4 2022.
- The 5-year median for Consolidated Net Income is -$20.5 million (2023), against an average of -$21.3 million.
- The widest annual swing landed in 2022, when Consolidated Net Income tumbled 330.7%; it then surged 73.13% in 2024.
- Tracing PYXS's Consolidated Net Income over 5 years: stood at -$16.4 million in 2021, then plunged by 119.87% to -$36.1 million in 2022, then soared by 55.2% to -$16.2 million in 2023, then slumped by 119.94% to -$35.6 million in 2024, then surged by 49.06% to -$18.1 million in 2025.
- Per Business Quant, the three latest PYXS Consolidated Net Income figures stand at -$18.1 million (Q4 2025), -$22.0 million (Q3 2025), and -$18.1 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -8.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Pyxis Oncology | 120.87 Mn | 103.97 Mn | 8.65 Mn | -18.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -18.12 Mn |
| Sep 30, 2025 | -22.00 Mn |
| Jun 30, 2025 | -18.07 Mn |
| Mar 31, 2025 | -21.67 Mn |
| Dec 31, 2024 | -35.57 Mn |
| Sep 30, 2024 | -21.20 Mn |
| Jun 30, 2024 | -17.30 Mn |
| Mar 31, 2024 | -5.34 Mn |
| Dec 31, 2023 | -16.17 Mn |
| Sep 30, 2023 | -23.65 Mn |
| Jun 30, 2023 | -16.47 Mn |
| Mar 31, 2023 | -19.89 Mn |
| Dec 31, 2022 | -36.10 Mn |
| Sep 30, 2022 | -27.67 Mn |
| Jun 30, 2022 | -25.56 Mn |
| Mar 31, 2022 | -31.38 Mn |
| Dec 31, 2021 | -16.42 Mn |
| Sep 30, 2021 | -11.62 Mn |
| Jun 30, 2021 | -5.94 Mn |
| Mar 31, 2021 | -35.73 Mn |
| Dec 31, 2020 | -4.58 Mn |
| Sep 30, 2020 | -3.19 Mn |